Investigation of intestinal permeability in inflammatory bowel disease using a novel evaluation method (Phase I, II study)

Investigation of intestinal permeability in inflammatory bowel disease using a novel evaluation method (Phas I, II study) - A novel evaluation method for intestinal permeability

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038461

Enrollment

132

Registered

2019-11-01

Start date

2018-08-05

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease (IBD)

Interventions

chitosan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Patients who physicians judge as inappropriate

Design outcomes

Primary

Measure	Time frame
Determination of chitosan dose for administarion (Phase I: after 1 and 4 hours) and evaluation of symptoms and blood examination (Phase I: by 1 month). Correlation between blood concentration level of chitosan and disease activity of IBD (Phase II. at administration).	—

Countries

Japan

Contacts

Public ContactShunji Ishihara

Shimane University Faculty of Medicine Internal Medicine II

si360405@med.shimane-u.ac.jp0853-20-2190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026